` GSS (Genetic Signatures Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

GSS
vs
S
S&P/ASX 300

Over the past 12 months, GSS has underperformed S&P/ASX 300, delivering a return of -56% compared to the S&P/ASX 300's +12% growth.

Stocks Performance
GSS vs S&P/ASX 300

Loading
GSS
S&P/ASX 300
Add Stock
www.alphaspread.com

Performance Gap
GSS vs S&P/ASX 300

Loading
GSS
S&P/ASX 300
Difference
www.alphaspread.com

Performance By Year
GSS vs S&P/ASX 300

Loading
GSS
S&P/ASX 300
Add Stock

Competitors Performance
Genetic Signatures Ltd vs Peers

S&P/ASX 300
GSS
0KHE
TMO
DHR
207940
Add Stock

Genetic Signatures Ltd
Glance View

Genetic Signatures Ltd. engages in the research and commercialization of identifying individual genetic signatures to identify diseases and disabilities. The company is headquartered in Sydney, New South Wales. The company went IPO on 2015-03-31. The firm is engaged in research and commercialization of identifying individual genetic signatures to aid in the diagnosis of infectious diseases and the sale of associated products into the diagnostic and research marketplaces. The firm is focused on the development and commercialization of its platform technology, 3Base. The Company’s 3Base platform technology provides hospital and pathology laboratories the ability to screen for an array of infectious pathogens, with a degree of specificity, in a rapid throughput (time-to-result) environment. The company also manufactures a Polymerase Chain Reaction (PCR) based products for the detection of infectious diseases under the EasyScreen brand. The Company’s EasyScreen sample processing kits are used to perform 3Base conversion and nucleic acid extraction and purification.

GSS Intrinsic Value
0.54 AUD
Undervaluation 41%
Intrinsic Value
Price
Back to Top